近日，中国眼视光行业迎来一个可能重塑未来格局的战略发布——"华誓国民视觉健康管理视联体"（下称"华誓视联体"）正式面向全社会亮相。这不仅仅是 一个新平台的登场，更是对行业"小、散、乱"传统格局的一次革命性整合。它标志着眼视光服务正从街边店的"手工作坊模式"，全面迈向一个由统一标准、 智能调度与品质背书的"产业互联网平台"时代。 一、战略升维之路：从专业品牌到"视光界滴滴"的平台跃迁 华誓视联体的诞生，根植于其旗下"美丽岛"品牌二十年心无旁骛的深耕。这段历程揭示了一条清晰的商业进化路径：在垂直领域建立绝对专业优势后，以技 术平台重构整个产业的价值链。 奠基期（"美丽岛"的深度）： 二十年如一日，专注于"多焦镜"这一复杂光学领域。通过服务超百万会员，不仅建立了技术壁垒，更积累了行业独一无二 的、连续动态的 "国人视觉健康数据库" 。此阶段的哲学是"深度创造信任"，为平台化奠定了专业与数据的双重基石。 升维期（"视联体"的平台化）： 深厚的专业与数据积淀，催生了质的飞跃。华誓体系以此为核心燃料，研发出全球视光行业首个垂直大模型——DeepVision 超级大脑。这标志着战略的根本性变革：从一个成功的产品品牌（"美丽 ...

Core Insights - Eye health is a crucial component of national health, affecting all age groups and significantly impacting quality of life and social burdens [1] - The "14th Five-Year Plan" emphasizes the prevention and treatment of myopia and cataracts, aiming for comprehensive coverage of cataract surgery capabilities by the end of 2027 [1] - The demand for eye health services is shifting from treatment to prevention and improved service quality, driven by economic development and an aging population [1] Group 1: Policy and Planning - The National Health Commission has identified eye diseases, particularly retinal diseases, as key areas for prevention and management, focusing on early screening and long-term care for the elderly [2] - The burden of neovascular age-related macular degeneration (nAMD) is expected to rise significantly, with the number of patients projected to increase from 4.5 million in 2020 to 8.8 million by 2050 [2] - If not addressed, approximately 75.7% of nAMD patients may progress to legal blindness within three years, highlighting the urgent need for effective interventions [2] Group 2: Innovation in Treatment - Bayer's Eylea 8mg has been launched nationwide, offering a more effective treatment option for nAMD patients with longer intervals between injections, potentially improving treatment adherence and quality of life [2][3] - Clinical trials have shown that Eylea 8mg can achieve similar vision improvement with fewer injections compared to the 2mg dosage, thus reducing the treatment burden on patients [3] - The drug's ability to decrease injection frequency addresses both patient and healthcare provider concerns, facilitating better long-term management of nAMD [3] Group 3: Comprehensive Eye Health Solutions - A comprehensive visual health protection system is essential for safeguarding national eye health, with initiatives targeting all demographics and life stages [5] - EssilorLuxottica has introduced new products for myopia management and adult visual health, alongside collaborations to enhance consumer insights and industry standards [5] - The "National Visual Health Report (2026 Edition)" is being developed to further address myopia prevention and expand into comprehensive eye health strategies [5] Group 4: Cross-Industry Innovations - EssilorLuxottica is also venturing into hearing health, addressing the significant market gap for hearing aids, with an estimated 1.25 billion people globally suffering from mild to moderate hearing loss [6] - The Nuance Audio hearing glasses, which integrate advanced hearing technology into stylish eyewear, have been launched to cater to individuals with hearing impairments [6][7] - Following FDA and CE certifications, the Nuance Audio product is set for accelerated introduction into global markets, including China, to benefit a larger user base [7]

Core Viewpoint - The event "EYE护视界 阅见未来" organized by Zeiss Optical, Sun Yat-sen University Eye Center, and Guangzhou Library focuses on public health issues related to myopia prevention among youth, promoting early screening and intervention for eye health [1][4]. Group 1: Event Overview - The event took place on September 14 at Guangzhou Library, featuring interactive zones where parents and children could learn about eye health and myopia prevention [1]. - The collaboration includes the establishment of a "Healthy Reading Promotion Practice Base" to enhance awareness and education on eye health [2]. Group 2: Expert Contributions - Professor Yang Xiao from Sun Yat-sen University emphasized the importance of early establishment of refractive development records for children and creating a suitable reading environment [3]. - Zeiss Optical's market manager highlighted the company's commitment to innovation in technology and services for lifelong eye health management [3]. Group 3: Community Engagement - The event provided free vision checks using professional equipment, reinforcing the concept of "early screening, early protection" [4]. - Interactive activities aimed to engage children in understanding the importance of eye protection, showcasing Zeiss's dedication to social responsibility and community health [4]. Group 4: Future Directions - Zeiss Optical plans to continue collaborating with various stakeholders to enhance eye health management solutions and promote a sustainable public health network [4].

Core Viewpoint - The article highlights Zeiss's commitment to promoting eye health awareness and management, particularly focusing on the youth and elderly demographics through its "Eye Health China Tour 2025" initiative, which aims to educate the public on vision care and provide free eye examinations [1][3][4]. Group 1: Event Overview - The "Eye Health China Tour 2025" has been launched in multiple cities including Beijing, Shanghai, and Guangzhou, focusing on "Youth Myopia Management" and "National Eye Health" [1]. - The initiative features innovative and culturally tailored activities, including free vision checks and educational sessions to raise awareness about eye health [1][3]. Group 2: Strategic Shift - Zeiss is transitioning from a product-centric approach to a user-centered philosophy, aiming to address consumer needs and enhance understanding of eye health solutions [2][5]. - The company emphasizes the importance of educating the public on common misconceptions about eye health, particularly regarding myopia in children [3][4]. Group 3: Target Demographics - Zeiss is particularly focused on the "youth and elderly" groups, addressing their specific vision health needs through tailored products and educational efforts [4][9]. - New products like the "Zeiss Growth Lens" are designed to slow myopia progression, while the "Zeiss Light 2.0 Progressive Lens" caters to the needs of older adults experiencing both myopia and presbyopia [4]. Group 4: Industry Trends - The eye care industry is undergoing a transformation driven by rising myopia rates, an aging population, and the increasing prevalence of digital lifestyles [8]. - There is a growing demand for personalized vision solutions, with Zeiss aiming to provide customized lenses for various activities and environments [6][7]. Group 5: Commitment to Industry Development - Zeiss is dedicated to enhancing the overall service quality and standards within the eye care industry, collaborating with medical institutions to establish industry benchmarks [8][9]. - The company’s initiatives, such as the "Zeiss Elite Academy," aim to empower industry professionals and improve service levels across the sector [9].

Core Viewpoint - The article discusses the recent financing round of Ruisi Technology, highlighting its innovative approach to myopia prevention through AI and visual neural intervention, and the establishment of a comprehensive "product-data-service" closed-loop system [2][4]. Financing and Investment - Ruisi Technology recently completed a multi-million financing round led by Huaxi Jinzhi, with existing shareholder Innovation Works increasing their investment [2]. - The funds will be allocated for clinical registration, sales enhancement, brand building, and ongoing product R&D [2]. Technology and Product Development - The company focuses on addressing the core issues of myopia prevention in adolescents, leveraging advanced AI technology and clinical evidence [2]. - Ruisi Technology is developing a "light-eye-brain" intelligent treatment closed-loop system, integrating optical stimulation, neural regulation, and AI feedback [2][3]. - The product system is characterized by "strong technology + soft standards," with innovations in hardware and algorithmic layers [2]. Clinical Validation and Efficacy - Clinical studies involving reputable medical institutions show that Ruisi Technology's products significantly outperform traditional myopia prevention methods [3]. - In a real-world study of nearly 200 cases over six months, the experimental group showed an average axial length increase of only 0.038mm, compared to 0.125mm in the control group [3]. Market Position and Future Outlook - Ruisi Technology aims to integrate treatment into daily life, promoting a seamless experience of "learning while treating" and "playing while adjusting" [3]. - The company has established a network of hundreds of professional institutions and over 1,000 stores, laying the groundwork for a long-term prescription treatment model [3]. - The co-founder expressed confidence in the company's unique advantages in original technology, real-world validation, and industry standards, projecting over 100% revenue growth year-on-year for the first half of 2025 [4]. Industry Insights - The eye care sector is recognized as a vast and mature market, with significant potential for growth driven by technological advancements [5]. - Investors have noted Ruisi Technology's differentiated products supported by clinical data, which naturally integrate into learning and entertainment scenarios, creating high industry barriers [5]. - The company's innovative "Far Vision Light Screen" product has gained recognition among eye care professionals and users, enhancing personalized myopia management services [5].

Group 1 - Raytheon Technology announced a joint investment with Jiangsu Huiding Optical Glasses Co., Ltd. and Optecon Vision Investment Co., Ltd. to establish Jiangsu Rayou Huiding Smart Glasses Co., Ltd., with Raytheon holding a 35% stake [1] - The establishment of the joint venture is expected to enhance the market expansion and strategic layout of Raytheon's smart glasses business [1] Group 2 - Raytheon Technology is recognized as the "first stock in e-sports equipment" on the Beijing Stock Exchange and has been listed in the "China's 500 Most Valuable Brands" for five consecutive years, with a brand value of 21.839 billion [3] - The Raytheon AI Magic Mirror (Raytheon Aura AI Smart Shooting Glasses) was officially launched on June 17, featuring a 1.2 million pixel camera, Sony IMX681 sensor, and Qualcomm Snapdragon AR1 chip, weighing only 39g [3] - Huiding Optical is one of the top three optical brands in China by lens sales, with a service network covering over 2,100 clients nationwide [3] - Optecon Vision is the first listed high-tech enterprise in the eye care sector in China, collaborating with over 1,500 well-known medical institutions and covering more than 2,000 professional optical channel partners [3] Group 3 - The partnership aims to leverage Huiding Optical and Optecon Vision's nationwide sales channels and user resources to accelerate the penetration of Raytheon AI Magic Mirror into offline channels [4] - The collaboration will also provide professional support for the development and upgrade of Raytheon's smart glasses through their teams specializing in myopia prevention and eye health management [4] - This initiative is part of Raytheon Technology's strategy to create a closed-loop ecosystem encompassing product development, channel access, and terminal services [4] Group 4 - According to the National Health Commission, the number of myopia patients in China has exceeded 700 million, with offline optical stores being the primary sales channel for glasses [6] - Euromonitor International indicates that offline optical stores will account for 81.8% of the eyewear sales channels in China by 2024, making them a crucial channel for promoting AI/AR glasses [6] - Raytheon Technology aims to transform into a diversified multi-channel layout, seizing the initiative in the industry chain layout [6] - The company is committed to providing an exceptional user experience and plans to collaborate with more ecosystem partners in product development, market expansion, and service ecosystem construction [6]

Core Insights - The conference focused on the launch of the MRT technology aimed at advancing myopia prevention and control, emphasizing the importance of technological innovation in personalized vision health management [1][5] - Experts highlighted the limitations of traditional vision screening and the breakthrough potential of MRT technology in providing effective solutions for myopia management [2][3] Group 1: Technological Advancements - Dr. Dong Xuechuan, a pioneer of MRT technology, explained how it utilizes precise data collection and customized solutions to address the shortcomings of traditional vision screening [2] - Professor Liu Xinting emphasized the need for a collaborative approach in myopia prevention, integrating technology with education, family, and society [2] - The MRT technology is positioned to drive standardization and professionalization within the eye care industry, injecting new vitality into its development [2][3] Group 2: Practical Applications - The founder of a chain of eye clinics shared successful case studies demonstrating the transition from a one-size-fits-all service model to a personalized service approach using MRT technology, resulting in increased user satisfaction and sustainable growth [3] - The global launch of the MRT technology was marked by a ceremonial event, indicating its readiness to enter the market and contribute to global myopia prevention efforts [4] Group 3: Future Outlook - The chairman of the company expressed a commitment to furthering research and development in MRT technology, aiming to enhance the global vision health landscape [5] - The event showcased a collective determination within the eye care industry to advance myopia prevention initiatives and improve visual health for a broader audience [5]

产品与技术 火眼睛晶的核心产品是 青少年儿童VR智能视训仪M1 ，该产品由火眼睛晶与中山大学中山眼科中心联合研 发。该设备采用全球领先的Pancake短焦光学技术， 整机重量仅160克，佩戴轻便舒适 ，并通过国家级视觉 健康安全标准和TUV防蓝光认证。 合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 近日， 深圳市火眼睛晶医疗科技有限公司 （以下简称"火眼睛晶"）宣布 完成 近千万元 天使轮融资 ，本次 融资由时代伯乐独家投资。资金将主要用于加速公司在眼视光XR智能医疗领域的研发迭代与市场拓展，推动 儿童青少年近视防控技术迈向智能化新阶段。 # 关于火眼睛晶 深圳市火眼睛晶医疗科技有限公司是一家专注于数字视光领域的创新型企业， 致力于通过 XR（扩展现实） +AI技术 为眼健康问题提供智能化解决方案 。公司成立于2022年，总部位于深圳，由前华为高层创立。火眼 睛晶以解决医疗资源不平衡为使命，通过技术创新推动眼视光领域的智能化发展。 在技术层面，火眼睛晶融合了 "周边离焦理论"与"无极变焦 ...